Shares of US drug developer XOMA Corp (Nasdaq: XOMA) crashed as much as 79% to $0.92, after the company posted disappointing late-stage results with its ophthalmic drug candidate gevokizumab.
XOMA announced the Phase III EYEGUARD-B study of gevokizumab in patients with Behcet's disease uveitis, run by its partner Servier, an independent French pharmaceutical research company, did not meet the primary endpoint of time to first acute ocular exacerbation.
Gevokizumab appeared to be well tolerated in the trial. Adverse events were comparable between gevokizumab and placebo treated groups.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze